VX-661: F508del CFTR Corrector for Cystic Fibrosis Research

Executive Summary: VX-661 (CAS 1152311-62-0) is a small-molecule corrector that rescues the folding and trafficking of the F508del-CFTR protein, the most prevalent cystic fibrosis (CF) mutation (APExBIO: VX-661 Product Page). It increases plasma membrane expression and chloride channel activity of mutant CFTR in vitro and in clinical studies (Tedman et al., 2025). VX-661 is often used in combination with potentiators (e.g., VX-770/ivacaftor), but this can modulate efficacy due to compound interactions. Quantitative benchmarks include a 25% restoration of chloride conductance (relative to wild-type) in human bronchial epithelial models under specified conditions. VX-661 is utilized exclusively for research and is not intended for medical or diagnostic use.

Biological Rationale

Cystic fibrosis is a life-shortening autosomal recessive disease caused by mutations in the CFTR gene, leading to defective chloride and bicarbonate ion transport across epithelial membranes (Tedman et al., 2025). Over 1700 CF-causing mutations have been documented, with F508del accounting for >70% of global alleles (Cystic Fibrosis Foundation). The F508del mutation disrupts the folding of the CFTR protein, causing endoplasmic reticulum (ER) retention and degradation instead of trafficking to the apical plasma membrane (see also: VX-661: Small-Molecule F508del CFTR Corrector…; this article extends those data by detailing new calnexin-dependent insights). These folding and trafficking defects reduce functional CFTR at the membrane, leading to impaired chloride secretion, thickened mucus, and chronic pulmonary disease. Pharmacological correctors like VX-661 provide a translational tool to rescue these molecular defects for research and drug development.

Mechanism of Action of VX-661 (F508del CFTR corrector)

VX-661 (1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide) acts as a small-molecule corrector. It binds directly to the misfolded F508del-CFTR protein, partially stabilizing its native conformation and facilitating ER export (Tedman et al., 2025). VX-661 enhances proper folding, reduces proteasomal degradation, and increases CFTR surface expression on bronchial epithelial cells. The compound operates synergistically with endogenous chaperones such as calnexin, which modulates later stages of CFTR assembly and influences corrector drug efficacy. When used with potentiators like VX-770 (ivacaftor), which increase channel open probability, VX-661 enables combined rescue of both trafficking and gating defects. However, chronic potentiator exposure can attenuate corrector efficacy, requiring precise experimental design (see: VX-661 and the Next Era of CFTR Correction…; this article clarifies practical workflow integration).

Evidence & Benchmarks

• VX-661 increases surface expression of F508del-CFTR by >2-fold in human bronchial epithelial (CFBE41o) cells after 24 h at 3 μM, 26°C (APExBIO).
• Combined VX-661 (chronic, 3 μM, 24 h) and VX-770 (acute, 10 μM) plus cAMP agonist increases CFTR chloride conductance to ~25% of non-CF controls (Tedman et al., 2025).
• Clinical studies show oral VX-661 at 10–150 mg daily for 28 days improves FEV1 and reduces sweat chloride in F508del homozygous/heterozygous CF patients (APExBIO).
• Calnexin is critical for robust pharmacological rescue of CFTR variants by VX-661, especially for mutations in the C-terminal domains (Tedman et al., 2025).
• VX-661 is soluble at ≥21.8 mg/mL in DMSO and ≥24.3 mg/mL in water; insoluble in ethanol (APExBIO).

Applications, Limits & Misconceptions

VX-661 (A2664) from APExBIO is intended for in vitro and preclinical research into CFTR folding, trafficking, and chloride channel rescue. It is validated in standard CF cell models (e.g., CFBE41o, primary human bronchial epithelial cells) and supports functional assays such as Ussing chamber and halide-sensitive dye flux protocols (see: Optimizing Cystic Fibrosis Research…; this article updates protocol recommendations with current storage and solubility data). VX-661 is not a therapeutic and should not be used in diagnostic or clinical treatment settings.

Common Pitfalls or Misconceptions

• VX-661 alone does not fully normalize CFTR function to wild-type levels; maximal rescue typically requires combination with potentiators and proper cAMP stimulation.
• Chronic co-administration of VX-770 can reduce the correction efficacy of VX-661, necessitating optimized treatment regimens.
• Some rare CFTR mutations show poor responsiveness to VX-661 due to proteostatic or domain-specific factors (Tedman et al., 2025).
• VX-661 is insoluble in ethanol and should only be dissolved in DMSO or water under controlled conditions.
• Long-term storage of VX-661 solutions is not recommended; fresh aliquots should be prepared as needed (APExBIO).

Workflow Integration & Parameters

For robust and reproducible results, VX-661 should be used as follows:

• Stock Preparation: Dissolve VX-661 in DMSO at concentrations ≥21.8 mg/mL or in water at ≥24.3 mg/mL; store aliquots at –20°C.
• Experimental Treatment: Treat cells at 3 μM VX-661 for 24 hours at 26°C for optimal plasma membrane rescue.
• Combination Protocols: For enhanced functional readout, combine chronic VX-661 with acute VX-770 and a cAMP agonist (.g., forskolin).
• Assays: Quantify apical CFTR expression by immunoblot or immunofluorescence; measure chloride conductance with Ussing chambers or fluorescent indicators.
• Storage and Handling: Avoid repeated freeze-thaw cycles; do not store working solutions long term.

For detailed, scenario-based workflow guidance, consult Optimizing Cystic Fibrosis Research: Practical Guidance…, which this article updates with current product batch specifications and mechanistic context.

Conclusion & Outlook

VX-661 (F508del CFTR corrector, A2664) from APExBIO is a validated, research-grade tool for dissecting the molecular pathology of cystic fibrosis and testing next-generation CFTR modulator strategies. Its robust performance in both in vitro and clinical protocols underpins its utility for benchmarking CFTR rescue, especially in combination regimens. Ongoing mechanistic studies (e.g., calnexin-dependence) refine precision use and highlight the need for variant-specific profiling. For authoritative product data and ordering, refer to the VX-661 (F508del CFTR corrector) product page. For in-depth mechanistic reviews and advanced protocol discussions, see VX-661: Advanced Mechanistic Insights for Precision CFTR… (this article adds updated evidence from recent mutational and chaperone studies).